WHO Consults On Draft Q&As To Support 2009 Guide On Evaluation Of Biosimilars
The Q&A document covers a wide a range of issues, ranging from licensing requirements to pharmacovigilance. However, it does not address interchangeability, switching, substitution, naming and shortages.
You may also be interested in...
A simplified process for registering and evaluating clinical trials promised by the EU Clinical Trial Regulation is finally set to become a reality.
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.
The 2021 work plan of PIC/S, the international group of pharmaceutical inspectorates, includes renewed efforts to carry out projects that could not be completed due to the coronavirus pandemic.